Ticker Details
Corvus Pharmaceuticals, Inc. Common Stock Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company. It is engaged in development and commercialization of novel immuno-oncology therapies that are designed to harness the immune system to attack cancer cells.
IPO Date:	March 21, 2016
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$1.71B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.20 | 3.68%
Avg Daily Range (30 D):	$0.71 | 5.22%
Avg Daily Range (90 D):	$0.39 | 3.63%

Institutional Daily Volume
Avg Daily Volume:	.63M
Avg Daily Volume (30 D):	4.91M
Avg Daily Volume (90 D):	2.37M

Trade Size
Avg Trade Size (Sh.):	185
Avg Trade Size (Sh.) (30 D):	106
Avg Trade Size (Sh.) (90 D):	106

Institutional Trades
Total Institutional Trades:	264
Avg Institutional Trade:	$1.73M
Avg Institutional Trade (30 D):	$1.85M
Avg Institutional Trade (90 D):	$1.85M
Avg Institutional Trade Volume:	.21M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$2.63M
Avg Closing Trade (30 D):	$3.26M
Avg Closing Trade (90 D):	$2.71M
Avg Closing Volume:	299.08K

News

Feb 2, 2026 @ 5:48 PM Momentum Is Just Starting for These 3 Rapid-Growth... Source: Nathan Reiff

Jan 23, 2026 @ 10:00 PM Corvus Pharmaceuticals Announces Closing of Upsize... Source: Corvus Pharmaceuticals, Inc.

Jan 22, 2026 @ 3:53 AM Corvus Pharmaceuticals Announces Pricing of Upsize... Source: Na

Oct 17, 2025 @ 2:00 PM Corvus Pharmaceuticals Announces Presentation of I... Source: Corvus Pharmaceuticals

Jul 10, 2025 @ 5:00 PM Interleukin-2 Inhibitors Clinical Trial Pipeline A... Source: Delveinsight

Financials
	TTM	Q3 2025	Q2 2025
Basic EPS	$-.18	$-.12	$-.1
Diluted EPS	$-.54	$-.12	$-.1
Revenue	$M	$M	$M
Gross Profit
Net Income / Loss	$-15.08M	$-10.16M	$-8M
Operating Income / Loss	$-38.86M	$-10.57M	$-10.26M
Cost of Revenue
Net Cash Flow	$-1.81M	$-11.82M	$9.69M
PE Ratio